Japan’s PMDA GMP Inspection Workflow

Japan’s PMDA GMP Inspection Workflow: A Complete Guide for Compliance

The Pharmaceuticals and Medical Devices Agency (PMDA)</strong) is Japan’s leading authority for drug evaluation, inspection, and post-marketing surveillance. PMDA collaborates with the Ministry of Health, Labour and Welfare (MHLW) to regulate Good Manufacturing Practice (GMP)</strong) for pharmaceutical products. Known for its precision and risk-based methodologies, the PMDA GMP inspection workflow</strong) plays a crucial role in ensuring the safety, efficacy, and quality of medicines produced in or imported into Japan. This article offers a detailed look at how PMDA plans, executes, and evaluates GMP inspections.

Regulatory Framework Governing PMDA Inspections

PMDA enforces GMP compliance under:

Pharmaceutical and Medical Device Act (PMD Act)

Ministerial Ordinance on GMP for Drugs and Quasi-drugs (Ordinance No. 179)

International harmonization with EMA, US FDA, and ICH guidelines

Japan is a member of PIC/S, aligning its GMP system with global expectations

When Does PMDA Conduct GMP Inspections?

Pre-Approval Inspections: Before product registration or import license approval

Periodic GMP Inspections: Scheduled based on facility type, product risk, and compliance record

For-Cause Inspections: Triggered by recalls, safety alerts, or adverse event reports

Foreign Site Inspections: For overseas manufacturers supplying to Japan

Also Read: How WHO Prequalification Enhances Market Access
PMDA Inspection Planning and Risk-Based Approach

Prioritizes

inspections based on:

Drug type (biologics, injectables, cytotoxics)

Previous inspection outcomes and CAPA effectiveness

Volume and frequency of product supply to Japan

Quality signals and market complaints

Facilities with critical findings or delayed CAPAs are flagged for expedited re-inspection

Foreign sites must submit GMP dossiers including past audits and validation summaries

PMDA GMP Inspection Workflow

Advance notice is issued to the facility (unless unannounced)

On-site inspection conducted by trained PMDA auditors using a defined checklist

Areas reviewed include:

QMS and deviation management

SOP compliance, document control, and batch records

Validation protocols (process, cleaning, and analytical)

Personnel training and change control

Data integrity, particularly electronic record compliance

Closing meeting held to summarize key observations

Final inspection report submitted to the applicant and MHLW

Deficiency Classification System Used by PMDA

Observations are categorized into:

Critical: Immediate risk to patient health or product quality

Major: GMP deviations with potential quality impact

Other: Technical issues requiring correction but low direct risk

Facilities with Critical findings must:

Submit CAPA within 15–30 days

Implement containment or recall actions if needed

Undergo re-inspection for GMP certificate renewal

Focus Areas in Recent PMDA Inspections

Inconsistent documentation and record reconciliation

Inadequate control of outsourced processes and CMOs

Gaps in stability testing design and monitoring

Failure to trend deviations or perform risk-based CAPA

Insufficient validation lifecycle for biologics and vaccines

Digitalization and Data Integrity Oversight

Increased scrutiny of electronic systems (ERP, LIMS, SCADA)

Audit trail review a mandatory component of GMP assessment

Expectations for ALCOA+ compliance in electronic documentation

Cybersecurity and access control policies must be documented and enforced

Licensing and GMP Certificate Issuance

Facilities must pass GMP inspection before PMDA will issue:

Manufacturer Accreditation Certificate

Import Certificate for foreign manufacturers

GMP certificates are valid for 5 years, subject to routine surveillance

PMDA reports can support global recognition and reliance mechanisms in the ASEAN and EU regions

Tips for Companies Preparing for PMDA Inspection

Review latest PMDA inspection findings and common citations

Maintain a Japanese-translated Site Master File and key quality documents

Ensure full traceability of all CAPAs with risk assessments and evidence of closure

Conduct internal audits using PIC/S aligned checklists and Japanese regulatory guidance

Prepare bilingual teams for inspector interaction, ensuring consistency across roles

Global Alignment and PIC/S Membership

Japan’s PMDA is a full member of PIC/S, enabling:

Joint inspections and training programs

Deficiency harmonization with EMA, TGA, and Health Canada

Participation in global GMP reliance frameworks

Supports data-sharing initiatives with WHO PQP and international donor agencies

Conclusion

The PMDA GMP inspection workflow is characterized by high standards of precision, risk prioritization, and regulatory transparency. For pharmaceutical manufacturers, aligning with PMDA expectations means maintaining robust QMS structures, validated processes, and demonstrable inspection readiness. With Japan playing an increasingly central role in international regulatory harmonization, success in PMDA inspections enhances not only local market access but also global regulatory credibility.